Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.48 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6476719 | 0.93 | CYSLTR2 (0.49) | CYSLTR2CYSLTR1IDO1TDO2SCN9A | |
| SCHEMBL6487119 | 0.85 | PPARG (0.44) | CYSLTR2CYSLTR1SCN9ASCN5A | |
| SCHEMBL6526673 | 0.85 | EGFR (0.46) | CYSLTR2CYSLTR1SCN9ASCN5A | |
| SCHEMBL6484332 | 0.81 | KIF11 (0.40) | CYSLTR2CYSLTR1SCN9ASCN5A | |
| SCHEMBL6485252 | 0.81 | CYSLTR2 (0.45) | CYSLTR2CYSLTR1IDO1TDO2 | |
| SCHEMBL6477587 | 0.80 | HSPD1 (0.43) | — | |
| SCHEMBL6488115 | 0.79 | CYSLTR2 (0.42) | CYSLTR2CYSLTR1IDO1TDO2 | |
| SCHEMBL6475810 | 0.78 | CYSLTR2 (0.42) | CYSLTR2CYSLTR1IDO1TDO2 | |
| SCHEMBL6477856 | 0.78 | CYSLTR2 (0.42) | CYSLTR2CYSLTR1IDO1TDO2 | |
| SCHEMBL6487120 | 0.77 | CYSLTR2 (0.44) | CYSLTR2CYSLTR1IDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6933322-B2 | Substituted naphthylenes for the treatment of non-insulin dependent diabetes mellitus | WYETH (US) | 2005-08-23 | — | — | US | disclosed |
| US-20030216442-A1 | Substituted naphthylenes for the treatment of non-insulin dependent diabetes mellitus | WYETH | 2003-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216442-A1 | Substituted naphthylenes for the treatment of non-insulin dependent diabetes mellitus | INSR, GPR119, SLC5A1 | CYSLTR2 4879/4885CYSLTR1 4791/4885IDO1 1894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.